18/02/2023
Non-small cell lung cancer (NSCLC) is a type of lung cancer that accounts for about 80% of all lung cancer cases. Here are some facts about non-small cell lung cancer:
✔ NSCLC is the most common type of lung cancer, accounting for about 80-85% of all cases.
✔ There are three main subtypes of NSCLC: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Adenocarcinoma is the most common subtype.
✔ Risk factors for NSCLC include smoking, exposure to secondhand smoke, exposure to certain chemicals (such as radon and asbestos), and a family history of lung cancer.
✔ Symptoms of NSCLC can include coughing, chest pain, shortness of breath, hoarseness, weight loss, and fatigue.
✔ Treatment options for NSCLC include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy.
✔ The prognosis for NSCLC depends on the stage of the cancer at the time of diagnosis. Early-stage NSCLC is more treatable than advanced-stage NSCLC.
✔ Prevention strategies for NSCLC include not smoking, avoiding exposure to secondhand smoke, and minimizing exposure to chemicals and other environmental risk factors.
✔ Regular screening with low-dose computed tomography (LDCT) is recommended for people who are at high risk of developing lung cancer, such as heavy smokers.
✔ In recent years, there have been significant advances in the treatment of NSCLC, particularly in the areas of targeted therapy and immunotherapy, which can help to improve outcomes for some patients.
✔ Like other forms of cancer, NSCLC can have a significant impact on patients and their families, both physically and emotionally. Support from healthcare providers, family members, and other caregivers can be important in helping patients cope with the challenges of the disease.
Tagrix is a drug shown to improve survival in patients with advanced non-small cell lung cancer with EGFR mutations...
If you are interested, then contact us on WhatsApp at +880-1922101029 or visit: https://emergencydrug.com/shop/tagrix-osimertinib-80-mg/
Tagrix indicate for the prevent epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)